Last week, pharmaceutical giant Eli Lilly (NYSE: LLY) announced that its cancer drug candidate enzastaurin failed its late-stage clinical trial. Despite this news, shares remained practically flat following the announcement. Was this drug central to Lilly's pipeline, or was it one of many oncology drugs that the company is testing? Should investors instead be worried about Lilly's upcoming patent expirations? What about the ever-present competition from diabetes powerhouse Novo Nordisk (NYSE: NVO)? Health-care analyst Max Macaluso discusses these topics in the following video.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.